{"filing":{"accession_number":"0001193125-26-349127","cik":"0001671858","ticker":"SPRY","company_name":"ARS Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-13","report_date":"2026-08-13","primary_document":"spry-20260813.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671858/000119312526349127/spry-20260813.htm"},"events":[{"id":27579,"run_id":25147,"accession_number":"0001193125-26-349127","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ARS Pharmaceuticals disclosed its financial results for the quarter ended June 30, 2026 via press release attached as Exhibit 99.1, including Q2 2026 net product revenue of $26.2 million, total revenue of $33.7 million, operating expenses of $82.3 million, and net loss of $62.3 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's commercial progress with neffy and financial trajectory.","company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","filing_date":"2026-08-13","form":"8-K","submitted_at":null,"items":[{"id":29165,"accession_number":"0001193125-26-349127","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ARS Pharmaceuticals disclosed its financial results for the quarter ended June 30, 2026 via press release attached as Exhibit 99.1, including Q2 2026 net product revenue of $26.2 million, total revenue of $33.7 million, operating expenses of $82.3 million, and net loss of $62.3 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's commercial progress with neffy and financial trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:06.281704+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":29165,"accession_number":"0001193125-26-349127","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ARS Pharmaceuticals disclosed its financial results for the quarter ended June 30, 2026 via press release attached as Exhibit 99.1, including Q2 2026 net product revenue of $26.2 million, total revenue of $33.7 million, operating expenses of $82.3 million, and net loss of $62.3 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's commercial progress with neffy and financial trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-14T03:01:06.281704+00:00","company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","filing_date":"2026-08-13"}]}